Myprotein Clear Whey Protein Water launch

Nichols’ new protein drink launch is all promise, with no financial proof yet for investors.

What the company is saying

Nichols plc is positioning itself as an innovator in the UK functional drinks market by announcing the upcoming launch of Myprotein Clear Whey Protein Water, a ready-to-drink product under a multi-year brand licence with THG plc. The company’s narrative is that this launch leverages the surging popularity of health and wellness products, aiming to capture a share of a £5.8bn market that grew 10% between 2025 and 2026. Nichols claims the new range will strengthen its position in a high-growth category, emphasizing that this is its first foray into protein-fortified drinks. The announcement repeatedly highlights the partnership with THG and the Myprotein brand, noting that Myprotein’s Vimto Clear Whey is already the top-selling clear whey protein product in UK retail. The company stresses the product’s features—zero sugar, 15g protein per 500ml bottle, and two flavours (Vimto and Raspberry Lemon)—and asserts that these have been popular in consumer testing, though no data is provided. The communication style is upbeat and confident, using phrases like “pleased to announce” and “expected to contribute to our delivery of long term, profitable growth,” but avoids any mention of risks, costs, or potential challenges. Notable individuals named include Andrew Milne (CEO) and Matthew Rothwell (CFO) of Nichols, and Neil Mistry (CEO of THG Nutrition), whose involvement signals institutional alignment but does not guarantee commercial success. The overall messaging is designed to assure investors that Nichols is executing a strategic, growth-oriented partnership, but it omits any hard financials or operational hurdles, focusing instead on market opportunity and brand strength.

What the data suggests

The only concrete numbers disclosed are industry-wide: the UK functional drinks market is valued at £5.8bn and grew 10% between 2025 and 2026. Product-level details include a 500ml bottle size, 15g protein content, and a recommended selling price of £2.99, but there are no figures for expected sales, production volumes, margins, or costs. No revenue, profit, or cash flow data is provided for Nichols plc, either for the new product or the company as a whole. There is also no information on capital expenditure, marketing spend, or the financial terms of the THG brand licence. The claim that Myprotein’s Vimto Clear Whey is the number one selling clear whey protein product in UK retail is presented as fact, but no sales figures or market share percentages are given. The gap between the company’s growth claims and the evidence is wide: while the announcement is rich in product and market context, it is devoid of any company-specific financial disclosures. An independent analyst would conclude that, based on the numbers alone, there is no way to assess the financial impact or viability of this launch. The lack of period-over-period data, targets, or guidance means investors are being asked to take the company’s growth narrative on faith.

Analysis

The announcement is upbeat and promotional, highlighting a forthcoming product launch and referencing a multi-year brand licence agreement. However, the majority of claims are either descriptive of the product or forward-looking, such as expectations for market demand, distribution, and long-term profitable growth. There is no disclosure of revenue, profit, cost, or sales volume figures for either the new product or Nichols plc as a whole. The only numerical data provided relates to the overall UK functional drinks market, not company-specific performance. While the partnership and product details are factual, the claims about strengthening market position, meeting consumer demand, and contributing to long-term growth are aspirational and unsupported by evidence. The absence of profitability or sustainability metrics means the signal cannot be stronger than weak_positive, and the language inflates the significance of the launch relative to the disclosed facts.

Risk flags

• ●Operational execution risk is high: Nichols is entering the protein-fortified drinks segment for the first time, and success depends on flawless manufacturing, distribution, and marketing. There is no evidence provided that the company has experience or a track record in this category.
• ●Financial disclosure risk is acute: The announcement omits all company-specific financial data, including revenue, profit, costs, or sales forecasts for the new product. This lack of transparency makes it impossible for investors to assess the potential return or downside.
• ●Forward-looking statement risk is substantial: The majority of the company’s claims are aspirational, projecting long-term growth and market success without any supporting evidence or interim targets. Investors are being asked to trust management’s vision without proof.
• ●Timeline risk is material: The product will not launch until September 2026, meaning any financial impact is at least two years away. This long execution window increases the chance of delays, market shifts, or competitive responses that could erode the opportunity.
• ●Market adoption risk is unquantified: While the company claims consumer testing has been positive and that the Myprotein brand is strong, no data is provided on actual demand, pre-orders, or retailer commitments. The risk is that consumer uptake may fall short of expectations.
• ●Brand licence risk is opaque: The economics of the multi-year agreement with THG are not disclosed, so it is unclear how profits (if any) will be shared or what minimum commitments Nichols has made. This could expose the company to unfavorable terms or hidden costs.
• ●Capital intensity risk is flagged by references to 'continued investment in innovation and category expansion,' but there is no detail on the scale or funding of these investments. If capital outlays are significant and returns are delayed, this could pressure Nichols’ balance sheet.
• ●Notable individual involvement is present—Neil Mistry, CEO of THG Nutrition, is named—but his participation only signals alignment at the partner level. It does not guarantee commercial success, distribution, or institutional follow-through for Nichols.

Bottom line

For investors, this announcement is a classic example of a company selling a growth story without providing the numbers needed to evaluate it. Nichols plc is touting a new product launch in a fast-growing market, but offers no financial data, no sales targets, and no evidence of consumer demand beyond generic claims. The partnership with THG and the use of the Myprotein brand are positives, but the economics of the deal are undisclosed and the launch is more than two years away. The absence of any revenue, profit, or cost figures means there is no way to model the potential impact on Nichols’ financials or to compare this initiative to other opportunities. The involvement of notable executives like Neil Mistry (THG Nutrition CEO) suggests institutional buy-in, but does not guarantee that the product will succeed or that Nichols will benefit materially. To change this assessment, Nichols would need to disclose projected sales volumes, margin expectations, capital requirements, and the financial terms of the brand licence. Investors should watch for concrete metrics in the next reporting period: actual orders, distribution agreements, early sales data, and any updates on costs or profitability. Until such data is provided, this announcement is best treated as a signal to monitor, not to act on. The single most important takeaway is that Nichols is asking investors to buy into a vision, not a proven business case—caution and patience are warranted.

Announcement summary

(LSE/AIM:NICL) Nichols plc announced the forthcoming launch of Myprotein Clear Whey Protein Water, a new ready-to-drink range under a multi-year Myprotein brand licence agreement. The UK functional drinks market is now valued at £5.8bn and grew by 10% between 2025 and 2026. The new 500ml ready-to-drink range will launch in September 2026 in two flavours: Vimto and Raspberry Lemon, each containing 15g of clear whey protein, with an RSP of £2.99. Nichols will produce and distribute the range through its established nationwide UK distribution network, building on its partnership with THG plc which began in 2021. Myprotein's Vimto Clear Whey is now the number one selling clear whey protein product across UK retail. Nichols expects the range to be distributed across convenience, wholesale and grocery channels through its UK retail network. The company projects that this launch is expected to contribute to its delivery of long term, profitable growth.

Disagree with this article?